Intellia Therapeutics (FRA:38I) Inventory Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:38I Intellia Therapeutics Inc FRA:38I
67 GF Score
Price €10.54
GF Value €11.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Intellia Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2026 was €1.81 Mil. Intellia Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2026 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Intellia Therapeutics's Days Inventory for the three months ended in Jun. 2026 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Intellia Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.00.

Intellia Therapeutics  (FRA:38I) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Intellia Therapeutics's Days Inventory for the three months ended in Jun. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=0/1.8061258539579*365 / 4
=0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Intellia Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=0 / 6.5871990073636
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Intellia Therapeutics Inventory Turnover Related Terms

Intellia Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Inventory Turnover Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:38I
67GF Score
Intellia Therapeutics Inc FRA:38I
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Inventory Turnover Calculation

Intellia Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=14.108905806341 / ((0 + 0) / 1 )
=14.108905806341 / 0
=N/A

Intellia Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover (Q: Jun. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2026 ) / ((Total Inventories (Q: Mar. 2026 ) + Total Inventories (Q: Jun. 2026 )) / count )
=1.8061258539579 / ((0 + 0) / 1 )
=1.8061258539579 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Intellia Therapeutics (FRA:38I) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of €10.54 is trading 7.1% below its estimated GF Value™ of €11.34. GuruFocus considers Intellia Therapeutics to be Fairly Valued.

Key valuation signals for FRA:38I:

  • Inventory Turnover:
  • GF Value™: €11.34 vs. price of €10.54 (7.1% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the FRA:38I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges NTLA:USA0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
67GF Score

Get the complete analysis for FRA:38I

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.54
Price
€11.34
GF Value